Filing Flows › Ovid Therapeutics (OVID) › Q2 2026 › vs Q2 2025
Ovid Therapeutics (OVID) Q2 2026 vs Q2 2025 (year over year)
Ovid Therapeutics's revenue fell $5.5M (-88%) from $6.3M in Q2 2025 to $733K in Q2 2026.
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $733K | $6.3M | −$5.5M | -88% |
| Other income, net | $689K | $389K | $300K | +77% |
| Net loss | $15.0M | $4.7M | $10.3M | +220% |
| Costs & expenses | $16.4M | $11.3M | $5.1M | +45% |
| Operating costs | $16.4M | $11.3M | $5.1M | +45% |
| Research & development | $10.0M | $6.5M | $3.5M | +54% |
| General & admin | $6.5M | $4.9M | $1.6M | +33% |
| Operating cash sources | $19.0M | $6.1M | $12.9M | +213% |
| Depreciation & amortization | $16K | $99K | −$83K | -84% |
| Share-based compensation | $1.4M | $1.2M | $212K | +17% |
| Cash used in operations | $17.6M | $4.8M | $12.8M | +269% |
| Net loss absorbed | $15.0M | $4.7M | $10.3M | +220% |
| Working capital & other | $4.0M | $1.4M | $2.6M | +186% |
Questions
How much did Ovid Therapeutics's revenue grow year over year in Q2 2026?
Ovid Therapeutics's revenue fell $5.5M (-88%) from $6.3M in Q2 2025 to $733K in Q2 2026.